Combination therapy using immunotoxins with interleukin-2
CA 1285875 C · Owner: Zimmerman, Robert · Inventors: Zimmerman, Robert; Issell, Brian; Stevens, Paul
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Anti-tumor activity in humans can be augmented by administering to the mammalian host a pharmacologically effective amount of mammalian IL-2 and at least one monoclonal antibody that binds selectively to human tumor cells and/or at least one immunotoxin that binds selectively to human tumor cells. The IL-2 and immunotoxin and/or monoclonal antibody are preferably administered separately to the host. The composition is useful for prophylactic or therapeutic treatment of such cancers as ovarian and breast cancer.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Granted July 9, 1991. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended July 9, 2008.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.